Naperville, IL -- (SBWIRE) -- 03/20/2015 -- Reportstack, provider of premium market research reports announces the addition of Irribow (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023 market report to its offering
Irribow (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023
Summary
Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients quality of life (QOL). In terms of volume, the IBS market is a large, albeit nave, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.
Irribow (ramosetron) is a product that was developed and is marketed by Astellas Pharma, and is available only in Japan for the treatment of males with IBS-D. In July 2014, Astellas announced that it had submitted an sNDA for Irribow for the treatment of females with IBS-D to the Ministry of Health, Labor and Welfare (MHLW) in Japan (Astellas Pharma, press release, July 14, 2014).
Scope
- Overview of IBS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Irribow including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Irribow for the top country from 2013 to 2023.
- Sales information covered for Japan.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for IBS.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of Irribow performance.
- Obtain sales forecast for Irribow from 2013-2023 in top country (Japan).
Complete report is available
http://www.reportstack.com/product/194757/irribow-irritable-bowel-syndrome-forecast-and-market-analysis-to-2023.html
Contact:
Roger Campbell
roger@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604